What is Immucell (NASDAQ:ICCC) earnings potential based on the current fundamentals?

If you have been keeping an eye on Immucell you know that now may not be the best time to buy. We currently estimate Immucell as undervalued. The real value is approaching 8.54 per share.
Published over a year ago
View all stories for ImmuCell | View All Stories
Macroaxis uses a strict editorial review process to publish stories and blog posts. Our publishers support our company and may receive a small commission when the partner links or references are utilized. Commissions do not affect the opinions or evaluations of our editorial team. The information our editors and media partners deliver is confidential and licensed for your sole use as a Macroaxis user. We reserve all rights to the content of this article, and therefore copying or distributing this story in whole or in part is strictly prohibited.

Reviewed by Michael Smolkin

We provide advice to complement the regular expert consensus on Immucell. Our dynamic recommendation engine utilizes a multidimensional algorithm to analyze the company's potential to grow using all technical and fundamental data available at the time.
Immucell Cp dividends can provide a clue to the current value of the stock. The company is not expected to issue dividends this year as it is trying to preserve or re-invest any of the funds available for distribution to stakeholders.
Typically, a company's financial statements are the reports that show the financial position of the company. There are three main documents that fall into the category of financial statements. These documents include ImmuCell income statement, its balance sheet, and the statement of cash flows. Potential ImmuCell investors and stakeholders use financial statements to determine how well the company is positioned to perform in the future. Although ImmuCell investors may use each financial statement separately, they are all related. The changes in ImmuCell's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on ImmuCell's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.
The goal of ImmuCell fundamental analysis is to do accurate financial forecasts. There are several possible objectives to fundamental analysis, such as projecting of ImmuCell performance into the future periods or doing a reasonable stock valuation. The intrinsic value of ImmuCell shares is the value that is considered the true value of the share. If the intrinsic value of ImmuCell is higher than its market price, buying is generally recommended. If it is equal to the market price, it is recommended to hold; and if it is less than the market price, then one should sell all shares ImmuCell. Please read more on our fundamental analysis page.

How effective is ImmuCell in utilizing its assets?

ImmuCell reports assets on its Balance Sheet. It represents the amount of ImmuCell resources that either has an existing economic value or will provide some form of benefits in the future. By effectively utilizing its assets, ImmuCell aims to generate revenue, control costs, drive operational efficiency, and enhance profitability. Optimizing asset utilization helps maximize shareholder value and maintain a competitive position in the Biotechnology space. To get a better handle on how balance sheet or income statements item affect ImmuCell volatility, please check the breakdown of all its fundamentals.

Are ImmuCell Earnings Expected to grow?

The future earnings power of ImmuCell involves the interaction of many company-specific, industry, and economic forces. Earnings estimates embody investors' opinions of ImmuCell factors such as sales growth, product demand, competitive industry environment, profit margins, and cost controls. ImmuCell stock prices adjust as these expectations change or are proven wrong. The main thing to remember is that equities with high expected earnings growth tend to underperform the market because it is usually difficult to meet the market's high expectations. Companies with low earnings expectations tend to do better than expected. Please use our latest analysis of ImmuCell expected earnings.

ImmuCell Gross Profit

ImmuCell Gross Profit growth is one of the most critical measures in evaluating the company. The Gross Profit growth rate is calculated simply by comparing ImmuCell previous period's values with its current period's values. Each time period you're measuring should be of equal lengths the increase or decrease, in a company's Gross Profit between two periods. Here we show ImmuCell Gross Profit growth over the last 10 years. Please check ImmuCell's gross profit and other fundamental indicators for more details.

Is ImmuCell valued correctly by the market?

Although in the United States, the Securities and Exchange Commission has enforced strong rules to prevent insiders from engaging in insider trading, finding insiders among active shareholders of Immucell is not uncomon. There are few distinct groups of Immucell stakehholders that the SEC considers insiders. Investors usually gain information through their work as corporate directors, officers, or employees. If these individuals share the information with a friend, family, or business partner and the person who receives the information exchanges stock in the company, he or shie is also an insider. Let's take a look at how the ownership of Immucell is distributed among investors.

Ownership Allocation

The market capitalization of Immucell is $55.35 Million. Immucell secures significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company outstanding shares. Since such a large part of the company is owned by insiders, it is advisable to analyze if each of these insiders have been buying or selling the stock in recent months. Please take into account that even companies with profitable outlook can generate negative future returns on their equity. If the true value of the firm is less than the current market value, you may not be able generate positive returns on investment in the long run.
Retail Investors
58.66%
Insiders
28.6%
Institutions
12.74%
Retail Investors58.66
Insiders28.6
Institutions12.74

Will Immucell slip impact its fundamentals?

Current variance is at 7.66. Immucell Cp exhibits very low volatility with skewness of 0.68 and kurtosis of 1.54. However, we advise investors to further study Immucell Cp technical indicators to ensure that all market info is available and is reliable. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Immucell's stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Immucell's stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different stocks as prices fall.

The Current Takeaway on Immucell Investment

Whereas some firms in the biotechnology industry are either recovering or due for a correction, Immucell may not be performing as strong as the other in terms of long-term growth potentials. In closing, as of the 20th of November 2022, we believe that Immucell is currently undervalued with low chance of distress in the next two years. Our current 90 days buy-sell recommendation on the company is Hold.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

Editorial Staff

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Ellen Johnson do not own shares of ImmuCell. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com